ReviewCurrent diabetes reports2024
Metformin: Past, Present, and Future.
Review in Current diabetes reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Comparison of pregnancy outcomes and physical conditions of infants in patients with gestational diabetes mellitus treated with metformin and insulin: a meta-analysis study.BMC pregnancy and childbirth · 2026Pooled it
- Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis.Reproductive sciences (Thousand Oaks, Calif.) · 2025Pooled it
- Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Cancer therapy-related cognitive impairment, part 2: from bench to bedside-and back: why candidate therapies for cancer therapy-related cognitive impairment fail to translate.Pharmacological reports : PR · 2026Review
- Metformin improves chronic rhinosinusitis with depressive-like behavior in mice by targeting TCF4 to inhibit the TLR4/NF-κB pathway.Scientific reports · 2026Article
- Antidiabetic and antioxidant effects of Armillaria gallica and Armillaria cepistipes extracts and their silver nanoparticles against streptozotocin induced diabetes in mice.Scientific reports · 2026Article
- Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions.Pharmacology research & perspectives · 2026Review
- Curdlan-Reinforced Chitosan/Polyacrylate Interpenetrating Hydrogels with Enhanced Mechanical Stability for Gastric Retention and pH-Responsive Drug Release.Gels (Basel, Switzerland) · 2026Article
- Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm.Reports (MDPI) · 2026Article
- Old Drug, New Science: Metformin and the Future of Pharmaceutics.Pharmaceutics · 2026Review
- Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database.Frontiers in endocrinology · 2026Article
- Intraovarian Platelet-Rich Plasma Therapy for PCOS: Unanswered Questions and Future Research Directions.Journal of clinical medicine · 2025Article
- Inhibition of hepatic gluconeogenesis in type 2 diabetes by metformin: complementary role of nitric oxide.Medical gas research · 2025Review
- The protective role of metformin against severe dengue disease in patients with type 2 diabetes mellitus: a preliminary report in Mexico.World journal of emergency medicine · 2025Article
- Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.British journal of cancer · 2025Review
- A novel molecularly imprinted sensor based on MOF-on-MOF architecture and Au nanoparticles for high-sensitivity electrochemical sensing of metformin.Mikrochimica acta · 2025Article
- Metformin Attenuates Spontaneous and Stimulated Myometrium Contractions in Rat Uterine Strips.The Eurasian journal of medicine · 2025Article
- Platelet-Rich Plasma in Reproductive Endocrinology: Mechanisms and Clinical Applications for Ovarian Reserve, PCOS, and Endometrial Receptivity.Biomedicines · 2025Review
- From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin.International journal of molecular sciences · 2025Review
- Therapeutic potential of traditional Chinese medicine and mechanisms for the treatment of type 2 diabetes mellitus.Chinese medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review provides the most recent update of metformin, a biguanide oral antihyperglycemic drug used as a first-line treatment in type 2 diabetes mellitus. RECENT
findingsMetformin continues to dominate in the world of antidiabetics, and its use will continue to rise because of its high efficiency and easy availability. Apart from type 2 diabetes, research is exploring its potential in other conditions such as cancer, memory loss, bone disorders, immunological diseases, and aging. Metformin is the most prescribed oral antidiabetic worldwide. It has been in practical use for the last six decades and continues to be the preferred drug for newly diagnosed type 2 diabetes mellitus. It reduces glucose levels by decreasing hepatic glucose production, reducing intestinal glucose absorption, and increasing insulin sensitivity. It can be used as monotherapy or combined with other antidiabetics like sulfonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, or insulin, improving its efficacy. Metformin can be used once or twice daily, depending on requirements. Prolonged usage of metformin may lead to abdominal discomfort, deficiency of Vitamin B12, or lactic acidosis. It should be used carefully in patients with renal impairment. Recent studies have explored additional benefits of metformin in polycystic ovarian disease, gestational diabetes mellitus, cognitive disorders, and immunological diseases. However, more extensive studies are needed to confirm these additional benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.